Scotiabank raised the firm’s price target on Liquidia (LQDA) to $36 from $34 and keeps an Outperform rating on the shares after Judge Timothy Kelly granted motions from both Liquidia and the FDA to dismiss United Therapeutics’ (UTHR) lawsuit against the FDA that alleged Yutrepia’s NDA amendment violated the FDA’s policy. The analyst, who calls the ruling “a best case scenario” ahead of Yutrepia’s May 24 PDUFA date, is increasing the firm’s view on the odds of success for Yutrepia to 95% from 90% as a result of this “legal de-risking event.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Legal Victory and Favorable Market Outlook Boost Liquidia Technologies to Buy Rating
- Liquidia up 13% to $15.85 in afternoon trading
- Strategic Legal Actions and Market Positioning Drive Buy Rating for Liquidia Technologies
- Liquidia Technologies: Buy Rating Affirmed Amidst Transformative Opportunities and Strategic Growth Potential
- Optimistic Buy Rating for Liquidia Technologies Driven by Yutrepia’s Regulatory Momentum and Promising Study Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue